The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Leishmaniasis in humans: drug or vaccine therapy?
Open accessAbstract
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells. Approximately 30 different species of Phlebotomine sand flies can transmit this parasite either anthroponotically or zoonotically through their bites. Leishmaniasis affects poor people living around the Mediterranean Basin, East Africa, the Americas, and Southeast Asia. Affected regions are often remote and unstable, with limited resources for treating this disease. Leishmaniasis has been reported as one of the most dangerous neglected tropical diseases, second only to malaria in parasitic causes of death. People can carry some species of Leishmania for long periods without becoming ill, and symptoms depend on the form of the disease. There are many drugs and candidate vaccines available to treat leishmaniasis. For instance, antiparasitic drugs, such as amphotericin B (AmBisome), are a treatment of choice for leishmaniasis depending on the type of the disease. Despite the availability of different treatment approaches to treat leishmaniasis, therapeutic tools are not adequate to eradicate this infection. In the meantime, drug therapy has been limited because of adverse side effects and unsuccessful vaccine preparation. However, it can immediately make infections inactive. According to other studies, vaccination cannot eradicate leishmaniasis. There is no perfect vaccine or suitable drug to eradicate leishmaniasis completely. So far, no vaccine or drug has been provided to induce long-term protection and ensure effective immunity against leishmaniasis. Therefore, it is necessary that intensive research should be performed in drug and vaccine fields to achieve certain results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Neutrophil Function: From Mechanisms to Disease
Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D., & Zychlinsky, A. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074942 · Cited by 1,708
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
Reithinger, R., Dujardin, J.-C., Louzir, H., Pirmez, C., Alexander, B., & Brooker, S. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70209-8 · Cited by 1,334
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Papahadjopoulos, D., Jacobson, K., Nir, S., & Isac, I. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90314-3 · Cited by 997
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
In Vivo Imaging Reveals an Essential Role for Neutrophils in Leishmaniasis Transmitted by Sand Flies
Peters, N. C., Egen, J. G., Secundino, N., Debrabant, A., Kimblin, N., Kamhawi, S., Lawyer, P., Fay, M. P., Germain, R. N., & Sacks, D. (2008) · Science · doi:10.1126/science.1159194 · Cited by 834
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Drug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Clinical Spectrum of Leishmaniasis
Pearson, R. D., & Sousa, A. D. Q. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.1.1 · Cited by 543
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537 · cited 3×
“Several clinical studies indicated that the best result of using LAmB in VL infection could arise at the dose of 20 mg/kg as recommended by WHO.”
InfluentialTissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Up-Regulation of Th1-Type Responses in Mucosal Leishmaniasis Patients
Bacellar, O., Lessa, H., Schriefer, A., Machado, P., Ribeiro de Jesus, A., Dutra, W. O., Gollob, K. J., & Carvalho, E. M. (2002) · Infection and Immunity · doi:10.1128/iai.70.12.6734-6740.2002 · Cited by 384
UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR)
Schofield, C. J. (1989) · Parasitology Today · doi:10.1016/0169-4758(89)90254-8 · Cited by 371
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Adler-Moore, J., & Proffitt, R. T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.21 · Cited by 339
Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani
Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-11 · Cited by 324
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L. (2012) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2012.01.003 · Cited by 294
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity
Marciani, D. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02864-2 · Cited by 290
Adler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
Gurunathan, S., Prussin, C., Sacks, D. L., & Seder, R. A. (1998) · Nature Medicine · doi:10.1038/4000 · Cited by 236
Alexander, J., Coombs, G. H., & Mottram, J. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6794 · Cited by 234
Cytokine profile and pathology in human leishmaniasis
Ribeiro-de-Jesus, A., Almeida, R. P., Lessa, H., Bacellar, O., & Carvalho, E. M. (1998) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1998000100020 · Cited by 219
Possibilities and challenges for developing a successful vaccine for leishmaniasis
Srivastava, S., Shankar, P., Mishra, J., & Singh, S. (2016) · Parasites & Vectors · doi:10.1186/s13071-016-1553-y · Cited by 201
Vaccines for leishmaniasis in the fore coming 25 years
Palatnik-de-Sousa, C. B. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.01.023 · Cited by 196
Leishmaniasis vaccine candidates for development: a global overview.
Khamesipour, A., Rafati, S., Davoudi, N., Maboudi, F., & Modabber, F. Z. (2006) · PubMed · Cited by 190
Recent updates and perspectives on leishmaniasis
Savoia, D. (2015) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.6833 · Cited by 187
First generation leishmaniasis vaccines: A review of field efficacy trials
Noazin, S., Modabber, F., Khamesipour, A., Smith, P. G., Moulton, L. H., Nasseri, K., Sharifi, I., Khalil, E. A. G., Bernal, I. D. V., Antunes, C. M. F., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.085 · Cited by 184
How protozoan parasites evade the immune response
Zambrano-Villa, S., Rosales-Borjas, D., Carrero, J. C., & Ortiz-Ortiz, L. (2002) · Trends in Parasitology · doi:10.1016/s1471-4922(02)02289-4 · Cited by 184
Chakravarty, J., Kumar, S., Trivedi, S., Rai, V. K., Singh, A., Ashman, J. A., Laughlin, E. M., Coler, R. N., Kahn, S. J., Beckmann, A. M., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.096 · Cited by 166
Liposomal amphotericin B as a treatment for human leishmaniasis
Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., Gaspani, S., Potet, J., & Chappuis, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.748036 · Cited by 160
Müller, K., van Zandbergen, G., Hansen, B., Laufs, H., Jahnke, N., Solbach, W., & Laskay, T. (2001) · Medical Microbiology and Immunology · doi:10.1007/s004300100084 · Cited by 157
Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis
Breton, M., Tremblay, M. J., Ouellette, M., & Papadopoulou, B. (2005) · Infection and Immunity · doi:10.1128/iai.73.10.6372-6382.2005 · Cited by 152
The Formation of Amphotericin B Ion Channels in Lipid Bilayers
Fujii, G., Chang, J.-E., Coley, T. R., & Steere, B. A. (1997) · Biochemistry · doi:10.1021/bi962894z · Cited by 148
Herman, J. D., Gallalee, J. V., & Best, J. M. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90689-7 · Cited by 140
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—A meta-analysis
Noazin, S., Khamesipour, A., Moulton, L. H., Tanner, M., Nasseri, K., Modabber, F. Z., Sharifi, I., Khalil, E. A. G., Vélez, I. D., Antunes, C., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.084 · Cited by 138
Recent developments and future prospects in the treatment of visceral leishmaniasis
Sundar, S., & Singh, A. K. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936116646063 · Cited by 135
Meheus, F., Balasegaram, M., Olliaro, P., Sundar, S., Rijal, S., Faiz, M. A., & Boelaert, M. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000818 · Cited by 131
Liposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic Mice
Lopez‐Berestein, G., Hopfer, R. L., Mehta, R. T., Mehta, K., Hersh, E. M., & Juliano, R. L. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/150.2.278 · Cited by 125
Fielding, R. M., Smith, P. C., Wang, L. H., Porter, J., & Guo, L. S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1208 · Cited by 117
Mizbani, A., Taheri, T., Zahedifard, F., Taslimi, Y., Azizi, H., Azadmanesh, K., Papadopoulou, B., & Rafati, S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.114 · Cited by 108
Wasunna, M. K., Njenga, S., Balasegaram, M., Alexander, N. D. E., Omollo, R., Edwards, T., Dorlo, T. P. C., Younis, B. M., Ali, M. H. S., Elamin, M. Y., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004880 · Cited by 106
Afrin, F., Ravindran, R., Anam, K., Sundaram, G. M., Pal, S., & Ali, N. (2002) · Infection and Immunity · doi:10.1128/iai.70.12.6697-6706.2002 · Cited by 104
Clinical Pharmacokinetics of Systemically Administered Antimycotics
Bellmann, R. (2007) · Current Clinical Pharmacology · doi:10.2174/157488407779422311 · Cited by 98
Iborra, S., Soto, M., Carrión, J., Alonso, C., & Requena, J. M. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.04.015 · Cited by 98
Machado‐Pinto, J., Pinto, J., da Costa, C. A., Genaro, O., Marques, M. J., Modabber, F. Z., & Mayrink, W. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01336.x · Cited by 96
Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis
Mistro, S., Maciel, I. D. M., de Menezes, R. G., Maia, Z. P. G., Schooley, R. T., & Badaró, R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis290 · Cited by 92
Quantitative proteomic analysis of amphotericin B resistance in Leishmania infantum
Brotherton, M., Bourassa, S., Légaré, D., Poirier, G. G., Droit, A., & Ouellette, M. (2014) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.05.002 · Cited by 89
Wasan, K. M., Morton, R. E., Rosenblum, M. G., & Lopez‐Berestein, G. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830716 · Cited by 82
Compartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and Its Lipid Formulations
Groll, A. H., Lyman, C. A., Petraitis, V., Petraitienė, R., Armstrong, D., Mickiene, D., Alfaro, R. M., Schaufele, R. L., Sein, T., Bacher, J. D., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-06 · Cited by 77
Distribution and metabolism of hexadecylphosphocholine in mice
Breiser, A., Kim, D. ‐., Fleer, E. A. M., et al. (1987) · Lipids · doi:10.1007/bf02535556 · Cited by 73
Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs
Rajasekaran, R., & Chen, Y. P. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.04.006 · Cited by 73
Espuelas, S. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg351 · Cited by 70
The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis
de Freitas, E. O., Leoratti, F. M. S., Freire-de-Lima, C. G., Morrot, A., & Feijó, D. F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00153 · Cited by 69
Vaccines that stimulate T cell immunity to HIV-1: the next step
McMichael, A. J., & Koff, W. C. (2014) · Nature Immunology · doi:10.1038/ni.2844 · Cited by 66
Vaccination with Leishmania Hemoglobin Receptor–Encoding DNA Protects Against Visceral Leishmaniasis
Guha, R., Gupta, D., Rastogi, R., Rajagopal, V., Krishnamurthy, G., Bimal, S., Roy, S., & Mukhopadhyay, A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006406 · Cited by 66
BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible Mice
Streit, J. A., Recker, T. J., Donelson, J. E., & Wilson, M. E. (2000) · Experimental Parasitology · doi:10.1006/expr.1999.4459 · Cited by 64
Wasan, E. K., Gershkovich, P., Zhao, J., Zhu, X., Werbovetz, K. A., Tidwell, R. R., Clement, J. G., Thornton, S. J., & Wasan, K. M. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000913 · Cited by 63
Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates
Cabezas, Y., Legentil, L., Robert-Gangneux, F., Daligault, F., Belaz, S., Nugier‐Chauvin, C., Tranchimand, S., Tellier, C., Gangneux, J., & Ferrières, V. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00563a · Cited by 62
Null mutants for the lmcpa cysteine proteinase gene in Leishmania mexicana
Souza, A. E., Bates, P. A., Coombs, G. H., & Mottram, J. C. (1994) · Molecular and Biochemical Parasitology · doi:10.1016/0166-6851(94)90057-4 · Cited by 62
Leishmania vaccine development: exploiting the host–vector–parasite interface
Reed, S. N., Coler, R., Mondal, D., Kamhawi, S., & Valenzuela, J. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1105135 · Cited by 60
Recent advances in vaccines for leishmaniasis
Requena, J. M., Iborra, S., Carrión, J., Alonso‐Moreno, C., & Soto, M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1505 · Cited by 59
Mahdavi, M., Mavandadnejad, F., Yazdi, M. H., Faghfuri, E., Hashemi, H., Homayouni, S., Farhoudi, R., & Shahverdi, A. R. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.02.006 · Cited by 59
Self-citationTewary, P., Jain, M., Sahani, M. H., Saxena, S. K., & Madhubala, R. (2005) · The Journal of Infectious Diseases · doi:10.1086/430348 · Cited by 56
Saljoughian, N., Zahedifard, F., Doroud, D., Doustdari, F., Vasei, M., Papadopoulou, B., & Rafati, S. (2013) · Parasite Immunology · doi:10.1111/pim.12042 · Cited by 55
Dendritic Cell-Based Vaccination Strategies: Induction of Protective Immunity against Leishmaniasis
Moll, H., & Berberich, C. (2001) · Immunobiology · doi:10.1078/0171-2985-00105 · Cited by 54
Badaró, R. J. D. S., Lôbo, I. M. F., Nakatani, M., Alvaro, M., Netto, E. M., Coler, R. N., & Reed, S. G. (2001) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702001000400008 · Cited by 51
Jamali, A., Mahdavi, M., Hassan, Z. M., Sabahi, F., Farsani, M. J., Bamdad, T., Soleimanjahi, H., Motazakker, M., & Shahabi, S. (2009) · International Immunology · doi:10.1093/intimm/dxn139 · Cited by 49
Singh, P. K., Sah, P., Meher, J. G., Joshi, S. A., Pawar, V. K., Raval, K., Singh, Y., Sharma, K., Kumar, A., Dube, A., et al. (2016) · RSC Advances · doi:10.1039/c6ra06007b · Cited by 49
The Role of Signaling via Aqueous Pore Formation in Resistance Responses to Amphotericin B
Cohen, B. E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00878-16 · Cited by 48
Khan, M. A. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl177 · Cited by 42
Conceição, J., Davis, R. E., Carneiro, P. P., Giudice, Â., Muniz, A. C., Wilson, M. E., Carvalho, E. M., & Bacellar, O. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004715 · Cited by 42
Poot, J., Spreeuwenberg, K., Sanderson, S. J., Schijns, V. E. C. J., Mottram, J. C., Coombs, G. H., & VERMEULEN, A. N. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.12.039 · Cited by 39
Petitdidier, E., Pagniez, J., Papierok, G., Vincendeau, P., Lemesre, J.-L., & Bras‐Gonçalves, R. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004614 · Cited by 39
Guha, R., Das, S., Ghosh, J., Naskar, K., Mandala, A., Sundar, S., Dujardin, J., & Roy, S. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.025 · Cited by 37
de Moura, T. R., Santos, M. L. B., Braz, J. D. M., Santos, L. F. V. C., Aragão, M. T., de Oliveira, F. A., dos Santos, P. L., da Silva, Â. M., de Jesus, A. R., & de Almeida, R. P. (2015) · Parasitology Research · doi:10.1007/s00436-015-4793-4 · Cited by 36
Choudhury, R., Das, P., De, T., & Chakraborti, T. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.02.008 · Cited by 34
Nare, B., Garraway, L. A., Vickers, T. J., & Beverley, S. M. (2009) · Current Genetics · doi:10.1007/s00294-009-0244-z · Cited by 31
Differences in Pharmacokinetics of Amphotericin B Lipid Formulations Despite Clinical Equivalence
Bellmann, R., Egger, P., & Wiedermann, C. J. (2003) · Clinical Infectious Diseases · doi:10.1086/374876 · Cited by 23
Tafaghodi, M., Eskandari, M., Khamesipour, A., & Jaafari, M. R. (2011) · Experimental Parasitology · doi:10.1016/j.exppara.2011.07.007 · Cited by 21
Patere, S. N., Pathak, P. O., Shukla, A. K., Singh, R. K., Dubey, V. K., Mehta, M., Patil, A., Gota, V. S., & Nagarsenker, M. S. (2016) · AAPS PharmSciTech · doi:10.1208/s12249-016-0553-8 · Cited by 14
Tafaghodi, M., Tabasi, S. A. S., & Payan, M. (2007) · Iranian journal of pharmaceutical sciences · doi:10.22037/ijps.v3.40340 · Cited by 12
Metadata
- Authors
- Ghorbani, M., & Farhoudi, R.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-12
- Volume
- Volume 12
- Pages
- 25-40
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2777159454
- Cited by
- 355
- References
- 83
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.